<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106817</url>
  </required_header>
  <id_info>
    <org_study_id>WCCTG 14-01</org_study_id>
    <nct_id>NCT04106817</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus</brief_title>
  <official_title>A Phase I, Open-label, Ascending Dose Study to Determine the Safety and Reactogenicity of a Wild Type Seasonal A/California/ H1N1 2009 Influenza Challenge Virus in Healthy Volunteers, Following a Single Intranasal Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WCCT Global</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>WCCT Global</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-controlled, open-label, single-center, dose-escalation study to determine the
      safety, infectivity, and immune responses elicited from of the potential influenza virus
      challenge strain. The study objective is to determine the dose with the optimal safety
      profile and infectivity rate of the viral challenge strain in healthy volunteers for use in
      subsequent challenge intervention studies to test potential influenza vaccines and/or
      therapeutics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2015</start_date>
  <completion_date type="Actual">August 10, 2015</completion_date>
  <primary_completion_date type="Actual">August 10, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Shedding</measure>
    <time_frame>Day 9</time_frame>
    <description>Number of participants with viral shedding, assessed from nasopharyngeal swabs using RT-PCR and cell culture assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>Day 60</time_frame>
    <description>Greater than or equal to 4-fold rise in HAI titer by study Day 60 relative to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Severity of AEs</measure>
    <time_frame>Day 60</time_frame>
    <description>The number of AEs in each Cohort rated as mild, moderate, or severe intensity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 10^6TCID50/dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live, wild-type A/California/H1N1 2009 influenza virus</intervention_name>
    <description>Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, as determined by medical history, physical examination, vital signs,
             echocardiogram, 12-lead ECG, and clinical safety laboratory examinations at baseline,
             as determined by the Investigator.

          -  Absent or low levels of detectable pre-existing antibodies to influenza virus
             subtypes, including as a minimum the challenge strain, as determined by an HAI titer
             of ≤10 prior to challenge.

          -  Non-smoker (no smoking within the last year and a history of less than 10 packs per
             year total) and agree to not use tobacco products during participation in the study.

          -  Female subjects of childbearing potential must:

               1. Not be breastfeeding

               2. Have a negative serum pregnancy test at screening and a negative urine pregnancy
                  test on Day -1

               3. Will use oral, implantable, transdermal, or injectable contraceptives for 30 days
                  prior to administration of the A/California/H1N1 2009 virus until the follow-up
                  visit is performed.

               4. Use another reliable form of contraception approved by the Investigator (eg,
                  intrauterine device, female condom, diaphragm with spermicide, cervical cap, use
                  of condom by the sexual partner or a sterile sexual partner) from the time of
                  screening until the follow-up visit is performed.

          -  Female subjects not of childbearing potential must:

               1. Be at least 1 year post-menopausal, or

               2. Be surgically sterile

          -  Male subjects able to father a child and sexually active with a female of childbearing
             potential, must agree to use a double barrier method of birth control (eg, condom with
             spermicidal foam, cream gel) and to not donate sperm during the study, from the day of
             enrollment until the Day 60 (±3) follow-up visit. If the female partner is using an
             effective method of contraception, a single barrier method of birth control for the
             male is acceptable.

          -  Comprehension of the study requirements, expressed availability for the required study
             period, and ability to be quarantined for up to 10 days and to attend the scheduled
             follow up visit.

          -  Negative alcohol and urine drug screening tests prior to entering quarantine.

          -  Being willing to adhere to the prohibitions and restrictions specified in this
             protocol

        Exclusion Criteria:

          -  Prior receipt of any influenza vaccine within the previous 2 years.

          -  Significant adulthood history of seasonal hay fever or a seasonal allergic rhinitis or
             perennial allergic rhinitis or chronic or nasal or sinus condition such as chronic
             sinusitis.

          -  Abnormal nasal structure including septal deviation and nasal polyps, or surgery to
             the nose or nasopharynx within 6 months of signing the informed consent form or recent
             (within the last 6 months) history of frequent or prolonged episodes of epistaxis.

          -  Suffering from asthma, bronchiectasis, emphysema, chronic obstructive pulmonary
             disease or any other chronic lung disease. A history of childhood asthma before the
             age of 12 is acceptable provided the subject is asymptomatic without treatment.
             Subjects with a single episode of wheezing after age 12 (lasting less than 8 weeks)
             can be included at the investigator's discretion.

          -  A female who is pregnant or who is breast feeding

          -  Diastolic BP, systolic BP or, pulse not consistent with normal vital signs, based on
             investigator judgment.

          -  Current use or use of intranasal corticosteroids within the last 30 days prior to the
             administration of the investigational virus product (Study Day 1).

          -  Presence of significant uncontrolled medical, neurological or psychiatric illness
             (acute or chronic) as assessed by the Investigator. This includes, but is not limited
             to, institution of new surgical or medical treatment for a chronic condition), or a
             significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months
             of screening and reconfirmed on Day -1 prior to challenge.

          -  Positive serology for HIV-1 or HIV-2, or HBsAg or HCV antibodies.

          -  Cancer or treatment for cancer, within 5 years, excluding basal cell carcinoma of the
             skin, which is allowed.

          -  Presence of immunosuppression or any medical condition that may be associated with
             impaired immune responsiveness, including, but not limited to, diabetes mellitus
             inflammatory bowel disease.

          -  Presently receiving (or history of receiving) or during the preceding 3-month period
             prior to screening, any medications or other treatments that may adversely affect the
             immune system such as allergy injections, immune globulin, interferon,
             immunomodulators, cytotoxic drugs or other drugs known to be frequently associated
             with significant major organ toxicity, or systemic corticosteroids (oral or
             injectable) azathioprine or mercaptopurine. Topical corticosteroids except intranasal
             will be allowed. Use of intranasal corticosteroids within the last 30 days prior to
             the administration of the investigational virus product (Study Day 1) is prohibited.

          -  Chronic condition requiring prescription or over-the-counter medicine, with the
             exception of vitamins.

          -  Anticipated presence of a household contact with documented severe immunosuppression
             (as defined by CD4 &lt; 200/mm³ or an absolute neutrophil count &lt; 1500/mm³), either as a
             result of disease and/or therapy.

          -  Anticipated presence of a household contact aged ≤ 5 years, aged &gt; 64 years, or a
             pregnant contact within 2 weeks following challenge.

          -  Current professional activity as a caregiver or healthcare worker who will return to
             work within 2 weeks following challenge.

          -  History of anaphylactic type reaction to egg or egg protein, adverse reaction to
             oseltamivir, a previous severe allergic reaction with generalized uticaria,
             angioedema, or anaphylaxis

          -  History of Guillain-Barre syndrome

          -  History of drug or chemical abuse in the year before the study.

          -  Receipt of any investigational virus product or nonregistered drug within the 30 days
             prior to challenge or currently enrolled in any investigational drug study or intends
             to enroll in such a study within the ensuing study period.

          -  Receipt of blood or blood products 6 months prior to challenge or planned
             administration during the study period.

          -  Blood donation in the last 26 weeks.

          -  Acute disease within 72 hours prior to challenge, defined as the presence of a
             moderate or severe illness with or without fever (as determined by the Investigator
             through medical history and physical examination), or presence of a fever ≥ 38ºC oral.

          -  Elevated white cell count above 10.5 x 109/L or an absolute neutrophil count above 7.5
             x 109/L.

          -  Any condition that, in the opinion of the Investigator, might interfere with the
             primary study objective.

          -  Drinks more than 1200 mL (or 5 cups of 240 mL per cup) of tea/coffee/cocoa/cola or
             other caffeinated beverage per day more than one day per week in the 2 weeks before
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <results_first_submitted>October 30, 2019</results_first_submitted>
  <results_first_submitted_qc>October 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2019</results_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled at a single site in California</recruitment_details>
      <pre_assignment_details>Enrolled participants with evidence of an infection, elevated blood pressure, or abnormal lab values prior to Day 1 did not receive the investigational virus product.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="27" upper_limit="44"/>
                    <measurement group_id="B2" value="30" lower_limit="23" upper_limit="43"/>
                    <measurement group_id="B3" value="29" lower_limit="21" upper_limit="44"/>
                    <measurement group_id="B4" value="33" lower_limit="21" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Viral Shedding</title>
        <description>Number of participants with viral shedding, assessed from nasopharyngeal swabs using RT-PCR and cell culture assay</description>
        <time_frame>Day 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Shedding</title>
          <description>Number of participants with viral shedding, assessed from nasopharyngeal swabs using RT-PCR and cell culture assay</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Shedding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Shedding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion</title>
        <description>Greater than or equal to 4-fold rise in HAI titer by study Day 60 relative to baseline</description>
        <time_frame>Day 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion</title>
          <description>Greater than or equal to 4-fold rise in HAI titer by study Day 60 relative to baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than 4-fold rise in HAI titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Greater than or equal to 4-fold rise in HAI titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Severity of AEs</title>
        <description>The number of AEs in each Cohort rated as mild, moderate, or severe intensity</description>
        <time_frame>Day 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Severity of AEs</title>
          <description>The number of AEs in each Cohort rated as mild, moderate, or severe intensity</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed through Day 60 (±3) for adverse events.</time_frame>
      <desc>AEs were defined as any untoward medical occurrence whether or not considered related to the investigational virus product.
The solicited signs and symptoms of influenza will not be reported as AEs as these constitute an endpoint of the study and will be recorded as such, unless a situation arises where it is the opinion of the Investigator to do so.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 106TCID50/dose)
Live, wild-type A/California/H1N1 2009 influenza virus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort/tightness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director of Regulatory Affairs</name_or_title>
      <organization>WCCT Global</organization>
      <phone>7207713080</phone>
      <email>erin.flynn@wcct.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

